Login to Your Account

Healthpoint's Leg Ulcer Cell Therapy Hits Phase III Trial

By Catherine Shaffer
Staff Writer

Wednesday, September 12, 2012
Healthpoint Biotherapeutics, of Fort Worth, Texas, began a Phase III trial of its allogeneic living cell bioformulation, HP802-247, for venous leg ulcers. The study will assess wound closure with HP802-247 plus compression therapy over a period of 12 weeks.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription